Literature DB >> 21361402

Prioritization of delayed vaccination for pandemic influenza.

Eunha Shim1.   

Abstract

Limited production capacity and delays in vaccine development are major obstacles to vaccination programs that are designed to mitigate a pandemic influenza. In order to evaluate and compare the impact of various vaccination strategies during a pandemic influenza, we developed an age/risk-structured model of influenza transmission, and parameterized it with epidemiological data from the 2009 H1N1 influenza A pandemic. Our model predicts that the impact of vaccination would be considerably diminished by delays in vaccination and staggered vaccine supply. Nonetheless, prioritizing limited H1N1 vaccine to individuals with a high risk of complications, followed by school-age children, and then preschool-age children, would minimize an overall attack rate as well as hospitalizations and deaths. This vaccination scheme would maximize the benefits of vaccination by protecting the high-risk people directly, and generating indirect protection by vaccinating children who are most likely to transmit the disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21361402      PMCID: PMC3772649          DOI: 10.3934/mbe.2011.8.95

Source DB:  PubMed          Journal:  Math Biosci Eng        ISSN: 1547-1063            Impact factor:   2.080


  39 in total

1.  Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009.

Authors:  Anthony E Fiore; David K Shay; Karen Broder; John K Iskander; Timothy M Uyeki; Gina Mootrey; Joseph S Bresee; Nancy J Cox
Journal:  MMWR Recomm Rep       Date:  2009-07-31

2.  School closure is currently the main strategy to mitigate influenza A(H1N1)v: a modeling study.

Authors:  V Sypsa; A Hatzakis
Journal:  Euro Surveill       Date:  2009-06-18

3.  Epidemiology of fatal cases associated with pandemic H1N1 influenza 2009.

Authors:  L Vaillant; G La Ruche; A Tarantola; P Barboza
Journal:  Euro Surveill       Date:  2009-08-20

4.  Severe respiratory disease concurrent with the circulation of H1N1 influenza.

Authors:  Gerardo Chowell; Stefano M Bertozzi; M Arantxa Colchero; Hugo Lopez-Gatell; Celia Alpuche-Aranda; Mauricio Hernandez; Mark A Miller
Journal:  N Engl J Med       Date:  2009-06-29       Impact factor: 91.245

5.  Estimating household and community transmission parameters for influenza.

Authors:  I M Longini; J S Koopman; A S Monto; J P Fox
Journal:  Am J Epidemiol       Date:  1982-05       Impact factor: 4.897

6.  Effectiveness and cost-effectiveness of vaccination against pandemic influenza (H1N1) 2009.

Authors:  Nayer Khazeni; David W Hutton; Alan M Garber; Nathaniel Hupert; Douglas K Owens
Journal:  Ann Intern Med       Date:  2009-12-15       Impact factor: 25.391

7.  Use of an inactivated vaccine in mitigating pandemic influenza A(H1N1) spread: a modelling study to assess the impact of vaccination timing and prioritisation strategies.

Authors:  V Sypsa; I Pavlopoulou; A Hatzakis
Journal:  Euro Surveill       Date:  2009-10-15

8.  Pandemic influenza--including a risk assessment of H5N1.

Authors:  J K Taubenberger; D M Morens
Journal:  Rev Sci Tech       Date:  2009-04       Impact factor: 1.181

9.  Strategies for mitigating an influenza pandemic.

Authors:  Neil M Ferguson; Derek A T Cummings; Christophe Fraser; James C Cajka; Philip C Cooley; Donald S Burke
Journal:  Nature       Date:  2006-04-26       Impact factor: 49.962

10.  Hedging against antiviral resistance during the next influenza pandemic using small stockpiles of an alternative chemotherapy.

Authors:  Joseph T Wu; Gabriel M Leung; Marc Lipsitch; Ben S Cooper; Steven Riley
Journal:  PLoS Med       Date:  2009-05-19       Impact factor: 11.069

View more
  2 in total

Review 1.  Optimal but unequitable prophylactic distribution of vaccine.

Authors:  Matt J Keeling; Andrew Shattock
Journal:  Epidemics       Date:  2012-03-07       Impact factor: 4.396

2.  Optimal Allocation of the Limited COVID-19 Vaccine Supply in South Korea.

Authors:  Eunha Shim
Journal:  J Clin Med       Date:  2021-02-04       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.